TABLE 3

Input for cost–benefit analysis

Variables categoryVariable nameDistribution#Value (base case)Relative change
(range)
Reference
Costs of first-line drugs per day €cTBDTriangular6.3±20%
(5.04–7.56)
[6]
Costs of WHO standard MDR-TB drugs per day €cMDR_TBTriangular101.04±20%
(80.83–121.25)
[6]
Costs of Ziehl–Neelsen microscopy €cZNTriangular6.41±20%
(5.12–7.69)
GOÄ no. 4513 (online supplementary section 2.b)
Costs of mycobacterial culture €cCultureTriangular23.31±20%
(18.65–27.97)
GOÄ no. 4540 (online supplementary section 2.b)
Costs of Xpert MTB/RIF €cXpertTriangular110.75±20%
(88.6–130.9)
GOÄ nos. 4780 and 4784 (online supplementary section 2.b)
Opportunity costs of blocking twin bed €cOppTriangular314.71±20%
(253.97–380.95)
Calculated from InEK (http://www.g-drg.de/cms/) data (online supplementary section 2.a)
Costs of diagnostic work-up €cDcsTriangular306.81±20%
(245.45–368.17)
Table 4 (online supplementary section 2.d)
Latency pending sputum culture result in  smear-positive daydCulture_SPNormal10.32±sd 8.9
(5.62–15.02)
Assessed (table 2)
Latency pending DST result in smear-positives daydResistance_SPNormal23.9±sd 8.9
(15.0–32.8)
Assessed (table 2)
Latency pending sputum culture result in  smear-negatives daydCulture_SNNormal13.17±sd 5.15
(8.02–18.32)
Assessed (table 2)
Latency pending DST result in smear-negatives daydResistance_SNNormal29.2±sd 7.2
(18.94–36.46)
Assessed (table 2)
Probability of MDR-TB in TB patientspMDR_TBLinear0.19660%/30%
(0.0–0.3)
Calculated (table 1)
PPV of positive sputum smearPPV_SmearLinear0.9474±95% CI
(0.8814–0.9827)
Calculated (table 1)
NPV of negative sputum smearNPV_SmearLinear0.9199±95% CI
(0.8955–0.9402)
Calculated (table 1)
PPV of Xpert MTB/RIF in smear-positivesPPV_Xpert_SPLinear1.0±95% CI
(0.9598–1.0)
Calculated (table 1)
PPV of Xpert MTB/RIF in smear-negativesPPV_Xpert_SNLinear0.8372±95% CI
(0.6930–0.9319)
Calculated (table 1)
NPV of Xpert MTB/RIF in smear-positivesNPV_Xpert_SPLinear1.0±95% CI
(0.4782–1.0)
Calculated (table 1)
NPV of Xpert MTB/RIF in smear-negativesNPV_Xpert_SNLinear0.9772±95% CI
(0.9623–0.9878)
Calculated (table 1)
PPV of Xpert MTB/RIF irrespective of smear statusPPV_XpertoverallLinear0.9474±95% CI
(0.8946–0.9786)
Calculated (table 1)
NPV of Xpert MTB/RIF irrespective of smear statusNPV_XpertoverallLinear0.9747±95% CI
(0.9612–0.9879)
Calculated (table 1)
Probability that WHO standard regimen is effectivepMDR_StandLinear0.9272±20%
(0.741–1)
[11]
Time left to discharge from hospital daysdDischargeTriangular26.78±20%
(21.24–32.14)
[6]
Costs of intrahospital contact investigation per TB index case €cContactTriangular105.81±20%
(84.65–126.97)
Adapted from [12]
Number of contacts to be investigatedpContactTriangular105–20Assumption (online supplementary section 2.e)
  • WHO: World Health Organization; MDR: multidrug-resistant; TB: tuberculosis; DST: drug susceptibility testing; PPV: positive predictive value; NPV: negative predictive value; GOÄ: Gebührenordnung für Ärzte (German medical fee schedule). #: in probabilistic sensitivity analysis.